Treatment method with SR18662 appreciably decreases advancement and proliferation of CRC cells. SR18662 displays enhanced efficacy in cutting down viability of numerous CRC mobile lines. Stream cytometry analysis pursuing SR18662 therapy demonstrates a rise in cells captured in either S or G2/M phas